

Kelly E Seaton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3357711/publications.pdf>

Version: 2024-02-01

47
papers

2,642
citations

304743

22
h-index

214800

47
g-index

49
all docs

49
docs citations

49
times ranked

4075
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of the HIV Vaccine Trials Network 702 Phase 2bâ€“3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	4.0	11
2	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021, 6, 56.	6.0	7
3	Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. <i>Frontiers in Big Data</i> , 2021, 4, 672460.	2.9	8
4	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. <i>Vaccine</i> , 2021, 39, 4641-4650.	3.8	1
5	Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. <i>Frontiers in Immunology</i> , 2021, 12, 709994.	4.8	4
6	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	17
7	Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection. <i>Npj Vaccines</i> , 2021, 6, 110.	6.0	11
8	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. <i>Nature Immunology</i> , 2021, 22, 1294-1305.	14.5	20
9	SIMON: Open-Source Knowledge Discovery Platform. <i>Patterns</i> , 2021, 2, 100178.	5.9	15
10	Vi-specific serological correlates of protection for typhoid fever. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	45
11	Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. <i>Statistical Methods in Medical Research</i> , 2020, 29, 78-93.	1.5	1
12	Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 233-246.	3.3	9
13	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , 2020, 72, 50-60.	5.8	15
14	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , 2020, 10, 13031.	3.3	10
15	A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. <i>EClinicalMedicine</i> , 2020, 21, 100313.	7.1	52
16	Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 434-439.	2.1	3
17	Persistence of vaccine-elicited immune response up to 14Âyears post-HIV gp120-NefTat/AS01B vaccination. <i>Vaccine</i> , 2020, 38, 1678-1689.	3.8	2
18	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	2.5	16

#	ARTICLE	IF	CITATIONS
19	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS ONE, 2019, 14, e0219142.	2.5	58
20	Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. Journal of Virology, 2019, 93, .	3.4	20
21	IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. Frontiers in Immunology, 2019, 10, 2582.	4.8	40
22	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. Journal of Clinical Investigation, 2019, 129, 4838-4849.	8.2	95
23	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. Journal of Infectious Diseases, 2018, 217, 1280-1288.	4.0	32
24	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Human Vaccines and Immunotherapeutics, 2018, 14, 2116-2127.	3.3	17
25	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 2018, 561, 479-484.	27.8	392
26	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature Medicine, 2018, 24, 1701-1707.	30.7	195
27	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. Journal of Immunology, 2018, 201, 1315-1326.	0.8	30
28	Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. MAbs, 2017, 9, 792-800.	5.2	43
29	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. Journal of Virology, 2017, 91, .	3.4	23
30	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. Journal of Virology, 2017, 91, .	3.4	20
31	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Medicine, 2017, 14, e1002435.	8.4	104
32	T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. JCI Insight, 2017, 2, .	5.0	164
33	Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight, 2017, 2, .	5.0	11
34	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS ONE, 2017, 12, e0179597.	2.5	29
35	Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. Vaccine, 2016, 34, 5344-5351.	3.8	11
36	HIV-1-negative female sex workers sustain high cervical IFN γ , low immune activation, and low expression of HIV-1-required host genes. Mucosal Immunology, 2016, 9, 1027-1038.	6.0	28

#	ARTICLE	IF	CITATIONS
37	Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. <i>Mucosal Immunology</i> , 2016, 9, 821-833.	6.0	22
38	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	12.6	191
39	Innate Activation of MDC and NK Cells in High-Risk HIV-1 Exposed Seronegative IV-Drug Users Who Share Needles When Compared With Low-Risk Nonsharing IV-Drug User Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 264-273.	2.1	23
40	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. <i>Journal of Virology</i> , 2015, 89, 9952-9961.	3.4	55
41	HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities. <i>PLoS ONE</i> , 2014, 9, e101863.	2.5	36
42	Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2014, 210, 99-110.	4.0	73
43	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. <i>Science Translational Medicine</i> , 2014, 6, 228ra39.	12.4	412
44	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	27.8	140
45	Multiple HIV-1-specific IgG3 responses decline during acute HIV-1. <i>Aids</i> , 2011, 25, 2089-2097.	2.2	79
46	Neurotensin receptor-1 inducible palmitoylation is required for efficient receptor-mediated mitogenic-signaling within structured membrane microdomains. <i>Cancer Biology and Therapy</i> , 2011, 12, 427-435.	3.4	32
47	N-Myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef. <i>Journal of General Virology</i> , 2008, 89, 288-296.	2.9	19